Blood test for neuroendocrine prostate cancer
2024
Dana Farber Cancer Institute, Boston, USA(1)
University of Trento, Trento, Italy(2)
University of Trento, Trento, Italy(2)
Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. Here, the researchers used patient plasma samples to develop a blood test that reliably detects neuroendocrine prostate cancer and can differentiate it from castration-resistant prostate adenocarcinoma. The test consists of a plasma cell–free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. The results were associated with clinical outcomes in two prospective phase II clinical trials.
Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation
Himisha Beltran(1), Francesca Demichelis(2)
Added on: 01-26-2024
[1] https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-23-0754/733104/Noninvasive-Detection-of-Neuroendocrine-Prostate?searchresult=1[2] https://www.drugtargetreview.com/news/113606/blood-test-developed-that-reliably-detects-nepc/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Newsletter+2+-+Unsponsored+-+18.01.24&utm_term=AI%27s+Precision+Medicine%2c+Aging+Secrets%2c+Neuroscience+Vision%2c+NEPC+Blood+Test+Breakthrough%2c+plus+much+more!+&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=XY6EDub7dH%2bvRK1RyFxMzh6vPk9Kz%2bS6L%2bmL4xBHDjpm0ESgLespekJi1jE%2bZSmQfVVADYTT%2fszM2in8n8Qfo%2fC5PeoDpQ3uP60e1d4mUmjX7qtWHwrO%2bmgEe4xUPDQUWeHZgXuQhWXDQY1QK0w3PkPsfoYJ9ohRVQ4stlN3HxOJvPRo9ss%2bCjEoyjvT7M%2fpxW%2bL8H8Z89KdAQe7AErH7JZ1%2bqz9lkEYOsd4VUB88%2bI%3d
